XL092: Clinical Trials

8 trials of XL092, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 active not recruiting, 1 enrolling by invitation. 8 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Recruiting 4, Active not recruiting 3, Enrolling by invitation 1
Phase 22Active not recruiting 1, Recruiting 1

Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer
Phase 3RecruitingExelixis6002026-12-182026-11-12
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC)
Phase 3Enrolling by invitationExelixis50002026-07-302026-10-28
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell
Phase 3RecruitingMerck Sharp & Dohme LLC7582026-04-092026-11-13
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma
Phase 3RecruitingMerck Sharp & Dohme LLC9042025-11-262026-11-12
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib, Everolimus - Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Phase 2 / Phase 3RecruitingExelixis4402025-07-212026-10-30
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab - Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3Active not recruitingExelixis6002024-06-072025-08-17
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma
Phase 3Active not recruitingExelixis3172023-01-012026-07-29
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
XL092, Atezolizumab, Regorafenib - Colorectal Cancer
Phase 3Active not recruitingExelixis9012022-09-072026-07-17

Conditions studied

Carcinoma, Renal Cell (3)  ·  Colorectal Neoplasms (3)  ·  Adenoma, Islet Cell (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Microsatellite Instability (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Prostatic Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Exelixis (6)  ·  Merck Sharp & Dohme LLC (2)

Countries

United States (8)  ·  Australia (6)  ·  France (6)  ·  Germany (6)  ·  Poland (6)  ·  South Korea (6)  ·  Spain (6)  ·  United Kingdom (6)  ·  Brazil (5)  ·  Italy (5)  ·  Argentina (4)  ·  Belgium (4)  ·  Chile (4)  ·  Czechia (4)  ·  Greece (4)

Results publications

PMID 39041200, PMID 40008409, PMID 40248950, PMID 41130252, PMID 42803451

NIH funding

2025 (1)